NCT00902187View on ClinicalTrials.gov

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Treatment of Overactive Bladder
Interventions
DRUG

Fesoterodine

A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg

DRUG

Fesoterodine

A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY